|Bid||223.20 x 1000|
|Ask||232.00 x 800|
|Day's Range||225.52 - 232.20|
|52 Week Range||117.58 - 242.97|
|Beta (5Y Monthly)||0.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 08, 2023 - Feb 13, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||239.09|
Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.
CAMBRIDGE, Mass., January 08, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products’ commercial launches.
If you're looking for stocks that can make dramatic gains quickly, it's hard to do any better than the biotechnology industry. Hardly a week goes by without at least one biotech stock shooting higher or tumbling lower in response to exciting news about experimental treatments. In 2023, all three of these drugmakers will report study results that are awfully important to their futures.